Bryn Pharma announced that it has agreed to a deal with drug delivery system firm Aptar Pharma to use its Bidose nasal device to deliver epinephrine for treating anaphylaxis.
The agreement grants Bryn worldwide exclusive right to use the two-dose nasal device to treat life-threatening allergic reactions with epinephrine. The pocket-sized FDA-approved device provides accurate two-shot nasal drug delivery.
"We are excited to partner with Aptar Pharma to develop a product that can provide patients with a life-saving treatment that fits in a pocket, is easy to use and complies with practice parameters,” said Bryn Pharma CEO David Dworaczyk.
